JPMorgan analyst James Gordon raised the firm’s price target on AstraZeneca to 14,000 GBp from 13,000 GBp and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Options Volatility and Implied Earnings Moves Today, July 25, 2024
- AstraZeneca now sees FY24 core EPS to increase by mid teens percentage
- AstraZeneca reports Q2 core EPS $1.98, consensus $1.95
- AstraZeneca put volume heavy and directionally bearish
- AstraZeneca announces global license agreement with Pinetree Therapeutics